GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.

The sales range reflects a decision to temporarily pause Gardasil/Gardasil 9 shipments into China beginning February 2025 through at least mid-year. The U.S. pharma giant expects adjusted EPS Of $ ...

compared with analysts estimates of $9.03 a share. Quarterly Gardasil sales of $1.55 billion missed Wall Street's estimates of around $1.8 billion, which has been pared back nearly 20% since the ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

The headwinds continue to play out despite Gardasil just last month nabbing an expanded approval in China to prevent certain HPV-related cancers and diseases in men ages 9 to 25, Merck pointed out ...

“This sales range reflects a decision to temporarily pause shipments of GARDASIL/GARDASIL 9 into China beginning February 2025 through at least mid-year,” the company stated. Published first ...

compared with analysts estimates of $9.03 a share. Quarterly Gardasil sales of $1.55 billion missed Wall Street’s estimates of around $1.8 billion, which has been pared back nearly 20% since the ...

Merck expects to earn $8.88 to $9.03 per share this year, compared with analysts estimates of $9.03 a share. Quarterly Gardasil sales of $1.55 billion missed Wall Street's estimates of around $1.8 ...

The drugmaker plans to temporarily pause shipments of its Gardasil vaccine to China at least ... expects adjusted earnings to range between $8.88 and $9.03 per share on $64.1 billion to $65.6 ...